Semaglutide vs Tirzepatide vs Retatrutide | GLP-1 Agonist Research Comparison | QSC
Semaglutide vs Tirzepatide vs Retatrutide — GLP-1 Agonist Comparison
The three leading incretin receptor agonists span mono, dual, and triple receptor activation. This comparison covers receptor targets, weight reduction magnitude in trials, mechanism differences, and research considerations for selecting the right compound for a given experimental design.
Why GCGR adds a third dimension to incretin research
Glucagon receptor (GCGR) drives hepatic glucose production and adipose lipolysis — effects that GLP-1R and GIPR do not cover. Adding GCGR agonism to retatrutide creates a compound that simultaneously reduces appetite (GLP-1R), enhances insulin sensitivity (GIPR), and increases lipolysis (GCGR). This triple mechanism is why retatrutide produces greater weight reduction than tirzepatide despite tirzepatide having stronger GLP-1R + GIPR activity.
Selecting the right compound for your research design
For GLP-1R-only mechanism studies: semaglutide. For dual GLP-1R/GIPR receptor dissection: tirzepatide + GLP-1R antagonist (exendin 9-39). For maximum weight loss model or triple receptor pharmacology: retatrutide. All three can be compared head-to-head in DIO mouse models with body weight, EchoMRI fat mass, glucose tolerance, and plasma insulin as primary endpoints.
❓
Frequently Asked Questions
What is the mechanism difference between semaglutide and tirzepatide?
Semaglutide is a GLP-1R mono agonist — appetite suppression, gastric emptying, glucose-dependent insulin secretion. Tirzepatide adds GIPR activity — GIP receptor on adipocytes and pancreatic beta cells enhances insulin secretion and may directly reduce adipose tissue. The GIPR contribution to tirzepatide efficacy is actively researched.
Why does retatrutide produce more weight loss than tirzepatide?
Retatrutide adds GCGR (glucagon receptor) to GLP-1R + GIPR. Glucagon receptor activation drives hepatic glucose production and adipose lipolysis — adding a direct fat mobilisation mechanism that tirzepatide lacks. The combination of appetite suppression (GLP-1R) + insulin potentiation (GIPR) + lipolysis (GCGR) produces the 24.2% reduction seen in the NEJM 2023 Phase 2 trial.
What is the QSC purity and COA format for these compounds?
All three supplied as lyophilised research vials, ≥99% HPLC purity, Janoshik independent COA. See individual research hubs for full specification data.
